Aerie Pharmaceuticals has completed enrollment in a phase 3 trial in Japan investigating netarsudil in patients with primary open-angle glaucoma or ocular hypertension, according to a press release.
The randomized, single-masked, multicenter, parallel-group study includes 245 patients who were randomly assigned to receive once-daily netarsudil ophthalmic solution 0.02% or twice-daily ripasudil hydrochloride hydrate ophthalmic solution 0.4%. The superiority study is evaluating the ocular hypotensive efficacy and safety of netarsudil vs. ripasudil over a 4-week period.
“We are pleased that